share_log

Recursion Pharmaceuticals | 8-K: Current report

SEC announcement ·  Apr 16 08:05
Summary by Moomoo AI
Recursion Pharmaceuticals, Inc., a clinical stage TechBio company, announced on April 16, 2024, the appointment of Dr. Najat Khan as Chief Research and Development Officer and Chief Commercial Officer. Dr. Khan, who brings extensive experience from her previous role as Chief Data Science Officer at Johnson & Johnson, will also join the Board of Directors at Recursion. Her initial term as a Class II Director will extend until the 2026 Annual Meeting of Stockholders. Dr. Khan's compensation includes a base salary of $570,000, eligibility for a 50% target bonus, participation in the Executive Change in Control and Severance Plan, and an initial equity grant valued at $8 million. Additionally, she will receive a one-time sign-on bonus of $500,000. These appointments and compensatory arrangements were disclosed...Show More
Recursion Pharmaceuticals, Inc., a clinical stage TechBio company, announced on April 16, 2024, the appointment of Dr. Najat Khan as Chief Research and Development Officer and Chief Commercial Officer. Dr. Khan, who brings extensive experience from her previous role as Chief Data Science Officer at Johnson & Johnson, will also join the Board of Directors at Recursion. Her initial term as a Class II Director will extend until the 2026 Annual Meeting of Stockholders. Dr. Khan's compensation includes a base salary of $570,000, eligibility for a 50% target bonus, participation in the Executive Change in Control and Severance Plan, and an initial equity grant valued at $8 million. Additionally, she will receive a one-time sign-on bonus of $500,000. These appointments and compensatory arrangements were disclosed in a Form 8-K filing with the SEC and accompanied by a press release. Dr. Khan's expertise in data science and AI is expected to drive Recursion's research and development efforts and build its commercial capabilities as the company continues to lead in the industrialization of drug discovery and development.

This announcement is a separate document:

Doc 1

Doc 2

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more